CH_Expat
Posted - 21 hours ago
$DAWN $IDYA $ARVN
Current Top-3 of my undervalued underperformers in Bioland. Missed the XBI-Run from 60 to 100 completely. Huge potential for doubles here.
IN0V8
Posted - 1 day ago
$IDYA Examine / Opportunity Stephens initiates coverage with overweight rating; PT $51
SpartanAlerts
Posted - 1 day ago
$TNYA as I was saying $SAVA hold for P3 readout $IOVA block buying and holding long term. Reminds me of $IDYA when it was below $10 and now it’s $30+
CH_Expat
Posted - 2 days ago
$IDYA @WSRX You have money to add? This is getting mad here.
DonCorleone77
Posted - 3 days ago
$IDYA $GILD Ideaya Biosciences appoints Stu Dorman as chief commercial officer Ideaya (IDYA) announced the appointment of Stu Dorman as chief commercial officer. Dorman has over 20 years of oncology and hematology experience. Prior to joining Ideaya, Dorman was the VP, U.S. oncology business unit head at Gilead Science (GILD).
CH_Expat
Posted - 5 days ago
$IDYA Casual -10% days because of a Kennedy. Okay. Nothing burger. Added more at 26.50 USD.
WSRX
Posted - 5 days ago
$IDYA EV of 900M. What a joke LOL
CH_Expat
Posted - 5 days ago
$IDYA Added 27.65 USD. 450 shares.
Wrangler4
Posted - 5 days ago
$AGIO $IDYA Go to your board ! Do you need instructions?
CH_Expat
Posted - 6 days ago
$IDYA What is going on here? Fat Finger? Cannot find any news.
CH_Expat
Posted - 6 days ago
$IDYA Bring it down, will double with pleasure at 27-28.
Tumble51
Posted - 1 week ago
$AGIO $IDYA take your MYNZ and put it on that board NOT THE FCUK HERE and your IDYA as well @EquityEdgeMax …or learn how to separate symbols …DAH
briefingcom
Posted - 1 week ago
$IDYA: IDEAYA Biosciences: Biocytogen announces IDEAYA’s nomination of development candidate IDE034, a potential first-in-class B7H3/PTK7 topo-i-payload bispecific ADC and option exercise https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20241111060603IDYA&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
DonCorleone77
Posted - 1 week ago
$IDYA Ideaya Biosciences nominates IDE034 as development candidate, exercises option Ideaya Biosciences announced the selection of IDE034, a B7H3/PTK7 topo-I-payload BsADC, as a development candidate and the exercise of its option for an exclusive worldwide license from Biocytogen Pharmaceuticals for potential B7H3/PTK7 BsADC program. Ideaya is targeting an investigational new drug, or IND, submission to the FDA in 2025 for IDE034, subject to satisfactory completion of ongoing preclinical and IND-enabling studies, to enable first-in-human study initiation. The option was exercised for an exclusive worldwide license from Biocytogen pursuant to the option and license agreement between Ideaya and Biocytogen. Ideaya will pay Biocytogen upfront and option exercise fees, along with additional development and regulatory milestone payments, commercial milestone payments, and royalties on net sales, totaling $406.5M, including up to $100M in development and regulatory milestone payments.
DonCorleone77
Posted - 1 week ago
$IDYA Biocytogen announces Ideaya's nomination of development candidate IDE034 Biocytogen announced that Ideaya Biosciences has exercised the option for an exclusive worldwide license for Biocytogen's B7H3/PTK7 BsADC program, IDE034, and has nominated it as a development candidate. Ideaya is targeting an Investigational New Drug submission to the U.S. FDA in 2025 for IDE034, pending the completion of ongoing preclinical and IND-enabling studies, to facilitate the initiation of first-in-human trials. Under the option and license agreement between Biocytogen and Ideaya, Biocytogen will receive upfront and option exercise fees, along with additional development and regulatory milestone payments, commercial milestone payments, and royalties on net sales, totaling $406.5M, including up to $100M in development and regulatory milestone payments. Based on the Human Protein Atlas database, B7H3/PTK7 has been reported to be co-expressed in multiple solid tumor types, including in lung, colorectal, and head and neck cancers at approximately 30%, 46% and 27%, respectively.
CH_Expat
Posted - 1 week ago
$IDYA One of the last bios standing still severly undervalued. Think about adding on Monday as I am waiting for a super sell-off in the beginning of next week.
Wrangler4
Posted - 1 week ago
$AGIO $IDYA You are at the wrong ticker with your BS
Dkll303
Posted - 2 weeks ago
$AGIO $AMRX $CPRX $IDYA you bring nothing to agios , you clown
Join @EingeLTrade ..he is long gone with his golden cross and a BO
What is today here , short covering once again !!! hahaha
CH_Expat
Posted - 2 weeks ago
$IDYA Probably tanking on a pretty ugly softbashing analysis of Leerink, giving a PT of 27 today.
DonCorleone77
Posted - 2 weeks ago
$IDYA Ideaya Biosciences reports Q3 EPS (60c), consensus (63c) "This was a transformational quarter for Ideaya, including completion of an oversubscribed ~$302.4 million follow-on financing, a late breaker oral presentation at ENA 2024 for IDE397 in heavily pre-treated MTAP-deletion urothelial and lung cancer patients, and a successful Type C meeting with the FDA to enable a potential registration-enabling trial for darovasertib in neoadjuvant uveal melanoma. Next, we received IND clearance for Werner Helicase inhibitor IDE275 with our partner GSK, representing our fifth potential first-in-class clinical program," said Yujiro S. Hata, Chief Executive Officer and Founder, IDEAYA Biosciences. "We continue to execute on our strategic vision to build a leading precision medicine oncology pipeline, and are on track to nominate our 6th, 7th, and 8th development candidate by year-end, including from our B7H3/PTK7 bi-specific topo-ADC, MTAP-deletion, and KAT6 pathway programs. We look forward to highlighting IDEAYA's potential first-in-class preclinical and clinical programs, and to continue to establish our scientific leadership in precision medicine oncology at our upcoming investor R&D day," said Michael White, chief scientific officer, Ideaya Biosciences.
CH_Expat
Posted - 2 weeks ago
$IDYA EV of this company now 1.2b. LOL.
CH_Expat
Posted - 10/31/24
$DAWN $SWTX $IDYA My current holdings. Most Bios were flying in the last six months. Almost everything looks overvalued, the three stocks did not join the run and look - in my opinion- undervalued considering the potential. We will see if they come back.
CH_Expat
Posted - 10/31/24
$IDYA The silent bleeding here is a very good opportunity to build a position.
CH_Expat
Posted - 10/29/24
$IDYA Doubled at 29.48 USD
biolover
Posted - 10/28/24
$IDYA this is an impressive small biotech. They have more serious attempts in oncology pursing top targets than anyone else. Now the WRN inh in MSI high tumors. The basic science is very strong here and likely to generate blockbuster drug if no toxicity. Next to go will be Pol Theta inh, another big target. There is also PARG inh. In addition to clinically active MTa2A inh and the uveal melanoma work. This is very impressive company with unique skills to target any enzyme
DonCorleone77
Posted - 10/28/24
$IDYA Ideaya Biosciences announces IND clearance for Werner Helicase inhibitor Ideaya Biosciences announced the clearance of an investigational new drug, or IND, application with the FDA for the initiation of a Phase 1 clinical trial to evaluate IDE275, a potential Werner Helicase inhibitor. IDE275 has demonstrated synthetic lethality preclinically in the high microsatellite instability biomarker setting, and the Phase 1 clinical trial will enroll patients having tumors characterized by MSI-High.
biolover
Posted - 10/25/24
$IDYA $TNGX synthetic lethality screen in MTAP deleted cell line . Top score MAT2A and PRMT5. Looks like MAT2A is at least as important as PRMT5 and cleaver way to suppress PRMT5 by depleting its substrate Idyea and Tango leaders in this emerging important field Very undervalued
biolover
Posted - 10/25/24
$IDYA $BMY $Idya $Tngx $Amgn BMS data looks slightly better than Amgen data. Idyea data from today look very competitive. Tango expected to deliver the best molecule soon with very excited CEO . Tango and Idyea clearly undervalued for this emerging important target/ field . Excellent durability of response by both BMS and Idyea today and Amgen earlier. Very exciting for cancer patients with MTAP deletion
bitra
Posted - 10/25/24
$IDYA overreaction